ImmuPharma PLC (LON:IMM)

ImmuPharma PLC (LON:IMM)


Share Price
14.71 p
Change
-0.3884 (-2.57 %)
Market Cap
£20.52 m
Proactive Investors - Run By Investors For Investors

ImmuPharma PLC RNS Release

Clinical Development Collaboration with Incanthera


RNS Number : 7735L
Immupharma PLC
31 December 2018
 

 

                                                                                                                                                                   31 December 2018

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

UPDATE ON NUCANT CANCER PROGRAMME

Clinical Development Collaboration with Incanthera

 

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update on its clinical development collaboration agreement for its Nucant cancer programme, with Incanthera Limited ("Incanthera"), a specialist oncology development company.

 

As announced on 7 December 2018, ImmuPharma alongside Incanthera are making good progress in finalising the 'Definitive Licence Agreement'. It has been agreed between both companies to extend the exclusivity period, which was initially granted to 31 December 2018, to 31 March 2019, in order to finalise the remaining parts of the agreement.

It is now envisaged that the 'Definitive Licence Agreement' will be finalised in the first quarter of 2019 and as such, a further update on this collaboration will be announced in due course.

Commenting, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, said:

"We are working diligently with Incanthera's management team to finalise the last remaining parts to the 'Definitive Licence Agreement' and look forward to updating the market and shareholders in Q1 2019."

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.com)

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 

 

 

 

 

 

 

 

 

About Incanthera Limited

 

Incanthera Limited was formed in 2010 as a spin-out from the Institute of Cancer Therapeutics at Bradford University and is targeting the treatment of cancer through a portfolio of unique technologies. Having successfully commercialised its lead product in 2017, it is actively acquiring technologies to further enhance its portfolio of cancer therapeutics. For more information, please visit: www.incanthera.com


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCLFFELFTLAFIT

ImmuPharma PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use